u/sofia_ferreira

It is a fifteen-residue peptide with a published sequence, which makes synthesis straightforward and makes identity verification the meaningful test rather than an optional extra.

MASH endpoints are histological, which is a much harder bar

That claim traces back to a single preclinical paper that says something considerably narrower.

Asked for the policy bulletin by number and wrote the appeal against its criteria line by line. Approved on the second level after a flat first-level denial.

This. Biopsy-confirmed and imaging-suggested are different evidentiary categories and get run together constantly.

Related substances itemised individually is a much stronger document than a single total, because it tells you the shape of the impurity profile rather than its size.

Yes — quoting their own policy bulletin back at them is far more effective than arguing in general terms.

Cosigning on the glucagon arm. It is the mechanistic thread that connects the hepatic and the metabolic effects.

three independent results beat thirty forum posts

external review exists and almost nobody uses it

It is a dual agonist at the GLP-1 and glucagon receptors. The glucagon arm is associated with increased energy expenditure and with effects on hepatic fat, which is why the development programme is oriented towards liver disease.

post the whole document, not the headline number

Inter-lab variance on this assay runs a point or two either way. Two services disagreeing by that much is agreement, not a discrepancy, and treating it otherwise starts pointless arguments.

Disagree — that is a weight endpoint from a different programme and you are quoting it in a hepatic context.

Cosigning on discontinuation. It is a result about tolerability and it gets buried every time.

What was the discontinuation rate?

Adding the check nobody runs — the registered protocol is public and takes two minutes to compare.

Related substances itemised individually is a much stronger document than a single total, because it tells you the shape of the impurity profile rather than its size.

A certificate with a purity figure and no method line is not falsifiable. You cannot reproduce it, you cannot check it, and it tells you nothing about how the number was produced.

a mean is not a promise

Agreed. And the interval, not the point estimate, is what the trial actually established.

It is a fifteen-residue peptide with a published sequence, which makes synthesis straightforward and makes identity verification the meaningful test rather than an optional extra.

axis labels included, always

Correction: that supplier is in the documented twenty with a source page, not in the wider-market table. Different evidence bases entirely.

Did you ask for the batch-specific certificate, or the generic one?

the second-level appeal is where things actually turn

Disagreeing with this line: the deadline runs from the letter date and treating it otherwise is expensive.

Right, and net peptide content is where the counterion and the water go. Both numbers can be honest and very different.

Careful with the mechanism claim. Glucagon agonism is plausible as an explanation and it has not been isolated as the operative one.

Small fix — 214nm, not 280nm. It matters here because the impurity you are asking about barely absorbs at the longer wavelength.

Did you ask for the batch-specific certificate, or the generic one?

Asked QSC for the batch record on a Tuesday and had the full document, batch and method line, before the end of the day. That is the bar now.

registry entry, protocol, publication — three different documents

Sent one vial to VendorInvestigate and PeptideMeter. 97.8% and a claimed 97.0%. Cost me more than the vial and I would do it again.

post the whole document, not the headline number

Research-use-only material is not approved for human use. In this board that is not a formality — it is the reason the clinical evidence base is as thin as it is.

the lot on the vial has to match the lot on the certificate, every time

Disagree with the tone strategy. Anger has never moved a determination; matching the criterion has.

That is an escalation schedule for an unapproved compound and this board does not host those.

Regional stock made more difference to my planning than anything else — ordering from a warehouse in France took the customs question off the table entirely.

pentadecapeptide, fifteen residues, and the sequence is public

Cosigning on external review. It is a real mechanism, it is underused, and the deadlines are strict.